Improved understanding of how host genetic variation affects resistance to microbial pathogens could lead to better treatment and/or prevention of infectious diseases. The lymphotoxin alpha (LTA)+250 and CD14À159 polymorphisms are associated with differences in susceptibility or outcome to several infections. We stimulated peripheral blood mononuclear cells (PBMC) from 22 healthy individuals with purified lipopolysaccharide (LPS), heat-killed Escherichia coli or Streptococcus pneumoniae. TNFaintracellular protein levels were measured by flow cytometry and mRNA was quantitated by RT-PCR. TNFa mRNA levels were higher in LTA+250GG subjects after 4 h incubation with LPS compared with LTA+250AA (T test, P ¼ 0.001). In contrast, after 8 h incubation with S. pneumoniae, there was slightly more TNFa mRNA in cells from LTA+250AA subjects. After 4 h incubation with LPS or E. coli, CD14À159TT subjects had higher TNFa mRNA levels than CD14À159CC (P ¼ 0.05, 0.033, respectively). Neither polymorphism affected the proportion of cells expressing intracellular TNFa protein. This suggests that the polymorphisms affected transcription and that other regulatory mechanisms affect production of TNFa protein. The effect of these two polymorphisms on TNFa mRNA production is stimulus dependent, with opposite effects observed for Gram-positive and Gram-negative stimuli.
Introduction
Many infectious diseases exhibit a broad range of severity, from asymptomatic infection to fulminant septic shock and death. While variations in the pathogenicity of different strains of bacteria are a major factor, there is also an inheritable susceptibility to death from infection. 1 As the prevalence of antibiotic-resistant bacteria is increasing, a better understanding of how host genetic variation affects resistance to specific infections could affect treatment and prevention.
Polymorphisms in immune-related genes affect susceptibility to infectious diseases and their complications. The lymphotoxin alpha (LTA)+250 polymorphic site is a guanine (G) to adenine (A) transition. Homozygotes for the A allele have a significantly greater risk of developing, 2, 3 and dying 4 from septic shock. In vivo, carriage of the LTA+250 A allele is associated with higher serum tumour necrosis factor alpha (TNFa) levels, 2, 4 which would be consistent with our current understanding of the pathogenesis of severe sepsis. 5 However, in vitro studies have produced conflicting results. 6, 7 In contrast to the studies of septic shock, LTA+250 was not associated with susceptibility to infection due to Trypanosoma cruzi, 8 hepatitis C virus, 9 Pseudomonas pseudomallei 10 and Plasmodium falciparum.
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This suggests either a more complex role for TNF in these conditions or that the effect may be pathogen specific.
Severe sepsis can be caused by Gram-positive or Gram-negative bacteria.
Gram-negative bacteria predominantly initiate an inflammatory response via a CD14, Toll-like receptor (TRL)-4 pathway, whereas Gram-positive bacteria act largely through a TLR-2 pathway which may or may not be CD14-dependent. 12 A cytosine (C) to thymidine (T) transition at CD14À159 was associated with both increased soluble plasma CD14 levels 13 and an increased risk of septic shock in a French cohort.
14 However a similar study in a German cohort found no such association. 15 We hypothesised that the impact of the LTA+250 and CD14À159 polymorphisms on TNFa production may depend on whether the individual is exposed to Gram-positive or Gram-negative bacteria. As previous in vivo and in vitro studies have only assessed cytokine levels in serum or culture supernatants, we assessed TNFa mRNA and intracellular protein concentrations. This avoids ambiguities associated with variable rates of TNFa release and catabolism in vivo and in vitro.
Results
Stimulated expression of TNFa mRNA peaks earlier than protein LTA+250 typing of 100 donors identified 22 healthy subjects who were homozygotes for either the G (n ¼ 10) or A allele (n ¼ 12). Peripheral blood mononuclear cells (PBMC) from these individuals were stimulated for 4 and 8 h with lipopolysaccharide (LPS), Escherichia coli (E. coli) or Streptococcus pneumoniae (S. pneumoniae). Levels of mRNA were elevated at 4 h (LPS, P ¼ 0.097; E. coli, Po0.001; S. pneumoniae, Po0.001), but declined to unstimulated levels after 8 h (Figure 1a) . In contrast, the TNFa protein expression remained elevated (Figure 1b) .
The LTA+250 polymorphism influences expression of TNFa mRNA but not protein At 4 h after stimulation with LPS, TNFa mRNA expression was significantly (P ¼ 0.001) higher in cells from LTA+250GG donors (Figure 2 ). In contrast, LTA+250AA cells showed a trend towards higher TNFa mRNA after exposure to S. pneumoniae (P ¼ 0.084). The percentage of monocytes expressing TNFa after incubation with the different stimuli was not influenced by the LTA+250 polymorphism ( Figure 3 ).
CD14À159 polymorphism influences expression of TNFa mRNA but not TNFa protein From the 22 donors, seven individuals were homozygous for CC at CD14À159, seven carried TT and eight were heterozygotes. No association was found between the polymorphism and the percentage of PBMC expressing TNFa or CD14 protein with or without stimulation (data not shown).
CD14À159TT was associated with higher TNFa mRNA levels compared to CD14À159CC (LPS, P ¼ 0.05; E. coli, P ¼ 0.033; S. pneumoniae, P ¼ 0.05) and CD14À159CT (LPS, not significant; E. coli, P ¼ 0.02; S. pneumoniae, P ¼ 0.048) after 4 h incubation (Figure 4 ). 
Discussion
We assessed TNFa mRNA and protein production in PBMC stimulated with LPS, E. coli and S. pneumoniae for 4 and 8 h. We also investigated whether the stimulus affected the influence of the LTA+250 and CD14À159 polymorphisms on TNFa expression (Table 1) . Both polymorphisms were associated with TNFa mRNA levels but not protein production. The T allele of the CD14À159 was associated with high TNFa mRNA when cells were exposed to any stimuli, while allele associations for the LTA+250 polymorphism depended on the stimulus. The critical role of the inflammatory stimulus has significant implications for in vitro studies assessing the functional effect of polymorphisms on inflammatory responses and for clinical association studies. The A allele of LTA+250 has been associated with susceptibility to sepsis and elevated plasma levels of TNFa. 4 This allele association has also been found in vitro using ELISA to measure LPS-induced TNFa after 20 h ) from healthy subjects (GG, n ¼ 10; AA, n ¼ 12) were stimulated (LPS, E. coli, S. pneumoniae) for 4 and 8 h and the per cent of PBMC expressing TNFa was determined by flow cytometry. Data shown are the median and 75 percentile of duplicate assays. No differences were identified by Mann-Whitney U tests. incubation. 16, 17 In contrast, we demonstrated significantly higher TNFa mRNA levels in LTA+250GG subjects 4 h after exposure to LPS, but not after exposure to E. coli or S. pneumoniae. However, S. pneumoniae induced slightly greater TNFa mRNA production in LTA+250AA subjects at 8 h. The variation with published results may be explained by the differing incubation times or the methodologies used. It is also possible that other polymorphisms carried in linkage disequilibrium mediate the effect of, or act in combination with, LTA+250 to influence TNFa levels. We have looked at several known TNFa polymorphisms (À238, À308, À376, À857, À863 and À1031) and have not found any that are in linkage disequilibrium with LTA+250 (data not shown).
The T allele of the CD14À159 can increase transcription activity and soluble CD14 levels by lowering the affinity of the CD14 regulatory region for Sp3, a factor known to inhibit transcription. 19 Carriage of the T allele of CD14À159 has also been associated with an increased mortality rate from septic shock, 14 although other groups could not confirm this finding. 15 Here we found that cells from individuals with the CD14À159TT genotype produced higher levels of TNFa mRNA after exposure to LPS, E. coli and S. pneumoniae.
Although we found a significant association between the number of PBMC expressing cell surface CD14 and LPS-stimulated production of intracellular TNFa (data not shown), the level of expression was not associated with the CD14À159 polymorphism. CD14 appears to be required for TNFa production after stimulation with LPS, E. coli and S. pneumoniae; 20, 21 however, the absolute level of membrane CD14 or soluble CD14 may not correlate with TNFa production. 22 While it is still unclear as to the influence CD14À159 has on CD14 levels, our studies support a pathogen-independent effect of this polymorphism on TNFa mRNA production.
While LTA+250 and CD14À159 affected TNFa mRNA levels, we did not find any association of intracellular TNFa protein levels with either polymorphism. It is possible that we sampled too early to detect a differential production in intracellular TNFa, but this seems unlikely as we demonstrated that intracellular TNFa increased with all stimuli and previous studies have shown a rise in extracellular TNFa in the same time period. 23 A possible explanation is the use of brefeldin to measure intracellular protein expression but not mRNA. Brefeldin creates a closed system whereby no intracellular communication, by way of secreted protein, can occur. This suggests that the mechanism(s) by which these polymorphisms (or the polymorphic sites they are in linkage disequilibrium with) alter TNFa production is via a pathway that includes protein secretion. It is also possible that the increase in TNFa transcription may be offset by regulatory mechanisms so that no increased production of TNFa results.
In conclusion, we have studied the effect on TNFa mRNA and intracellular protein production of the LTA+250 and CD14À159 polymorphisms using LPS, E. coli and S. pneumonia as the stimuli. The effect of LTA+250 on TNFa mRNA production was pathogendependent, with opposite associations observed for the Gram-positive stimulus (S. pneumoniae) and the Gramnegative stimuli (E. coli, LPS). This finding has significant implications for the interpretation of clinical association studies involving these and other inflammatory gene polymorphisms and for future laboratory assessment of the functional significance of inflammatory gene polymorphisms.
Materials and methods

Subjects
A total of 22 healthy subjects (mostly hospital and laboratory staff) (10 males and 12 females; mean (range) age 35 years (23-56 years)) were selected from a screen of 100 donors on the basis of homozygosity at LTA+250. These subjects had no chronic illness, were not on any medications and were not affected by any acute medical condition at the time of study. The Medical Ethics Committee of Royal Perth Hospital approved this study. All participants gave written and informed consent. Genotyping for the LTA+250 G/A and the CD14À159 C/T genetic polymorphisms EDTA-treated blood samples were centrifuged for 10 min at 2500 rpm at room temperature and the buffy coat collected and stored at À801C. Genomic DNA was isolated from 250 ml buffy coat with the QIAamp DNA Mini Blood Kit (Qiagen), according to the manufacturer's instructions. Analysis of the LTA intron 1 gene polymorphism was performed as described. 4 The forward and reverse primers were 5 0 -AGAAGGGGACAAGATG-CAGTC-3 0 and 5 0 -CCGTGCTTCGTGCTTTGGACTA-3 0 , respectively. Genomic DNA (40 ng) was added to 25 ml of reaction mixture containing 12 pmol of each primer (Geneworks), 1.5 mM MgCl 2 (Biotech), 2.3 U Tth plus DNA polymerase (Biotech) and polymerase buffer (Biotech). Cycling conditions were 5 min at 951C, followed by 35 cycles of 1 min at 951C, 1 min at 651C and 1 min at 721C, and finally 10 min at 721C. A product of 282 bp was generated and subsequent restriction digest with Nco1 yielded fragments of 201 and 81 bp (LTGG), and 282 bp (LTAA) separated by electrophoresis on 3.5% agarose gels containing ethidium bromide. CD14À159 alleles were determined by PCR-RFLP as described.
14 The CD14 forward and reverse primers were 5 0 -TGCCAGGAGACACAGAACCC-3 0 and 5 0 -TGTCATT-CAGTTCCCTCCTC-3 0 , respectively. A product of 166 bp was digested with HaeIII, with the T polymorphic base not cut by the restriction enzyme. Fragments were separated on 3% agarose gels with ethidium bromide.
Preparation of S. pneumoniae and E. coli S. pneumoniae, serotype 3 (ATCC 6303) and E. coli (ATCC 4157) were obtained from American Type Culture Collection. Colonies were cultured overnight at 371C on horse blood agar plates in the absence and presence of 5-10% CO 2 for E. coli and S. pneumoniae, respectively. Colonies of E. coli and S. pneumoniae were used to inoculate 10 ml of Nutrient Broth and Haemophilus Test Medium, respectively. The inocula were incubated for 16 h at 371C and added to 500 ml of the same media. Bacteria were grown to late logarithmic phase growth, washed two times with warm PBS and killed by incubation at 651C for 20 min as described. 24 Bacteria were counted in a haemocytometer and killing was confirmed by cultivation on horse blood agar. Bacteria were stored at À801C in 20% glycerol/80% PBS.
Stimulation of PBMC with LPS, S. pneumoniae and E. coli PBMC were isolated from all subjects by density gradient centrifugation of heparinised blood on Ficoll and stored in liquid nitrogen in 10% DMSO/90% heat-inactivated (HI) FCS. Thawed PBMC were washed once and resuspended at 10 6 cells/ml in RPMI/10% HI FCS. Cells (500 ml) were aliquoted into 6 ml round-bottom polypropylene tubes (Falcon) precoated with RPMI/10% HI FCS. Aliquots (500 ml) of RPMI/10% HI FCS or 10 mg/ml LPS (from E. coli 0111:B4; Sigma Chemical Co.), 10 7 E. coli or 10 7 S. pneumoniae in RPMI/10% HI FCS were added. The LPS content of 10 7 E. coli is approximately 20 ng. 25 Maximal TNFa production was obtained over a broad range of LPS concentrations (10 ng/ml to 10 mg/ml) (data not shown) in agreement with other studies. 26 Brefeldin A (Sigma Chemical Co.; final concentration 10 mg/ml) was added to cells to be analysed by flow cytometry. PBMC were incubated for 4 and 8 h at 371C (5% CO 2 ).
Measurement of TNFa mRNA by real-time RT-PCR RNA was extracted from PBMC using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. Briefly, cells were pelleted (6 min, 5000 rpm, room temperature) and lysed in 350 ml RLT buffer. The lysate was filtered through a QIAshredder (Qiagen) spin column and stored at -801C until RNA was isolated and reconstituted in 30 ml of RNAase free water (ICN) and stored at -801C until used. RNA (6 ml) was used for firststrand cDNA synthesis using Omniscriptt Reverse Transcriptase (Qiagen) and oligo (dT) 15 primers (Promega) in a final volume of 20 ml. Samples were stored at À201C.
TNFa mRNA was quantitated with primers located in exon 1 (forward primer: 5 0 -GTGCTTGTTCCTCAGCCT CT-3 0 ) and spanning exon 1 and 2 junction (reverse primer: 5 0 -TGGGGAACTCTTCCCTCTG-3 0 ) yielding a 107 bp amplicon. b-actin, internal control, was amplified with the forward primer spanning the exon 2 and 3 junction (5 0 -GATGACCCAGATCATGTTTGA-3 0 ) and the reverse primer spanning the exon 3 and 4 junction (5 0 -GACTCCATGCCCAGGAAGGAA-3 0 ), resulting in a product of 459 bp. For PCR amplification on the LightCyclert (Roche), a 20 ml reaction mix was prepared containing 20 ng/ml of each primer (Geneworks), 800 mM dNTPs (Gibco), 0.25 mg/ml BSA (CSL), 1/20 000 dilution of SYBR s Green I (Sigma, cat no. S9430), 1.5 U Platinum Taq DNA Polymerase (Gibco) and 5 ml of a 1/20 dilution of first strand cDNA. Using the PCR Optimisation Kit (Boehringer Mannheim), an optimal PCR buffer was determined for b-actin (3 mM MgCl 2 , pH 8.6) and TNFa (2 mM MgCl 2 , pH 9.2). Cycling conditions for amplification of TNFa were 951C for 5 min, followed by 40 cycles of 601C for 5 s and 721C for 15 s, followed by 961C for 1 s, 601C for 5 s, 991C for 1 s and finally 401C for 30 s. Apart from an annealing temperature of 621C and only 35 cycles, the b-actin amplification conditions were the same. The PCR products were run on an agarose gel and visualised by ethidium bromide staining to confirm amplification of a single product of correct size. Negative controls were routinely performed by running PCR without cDNA template (DEPC H 2 O). Serial 10-fold dilutions of plasmids (TNFa/pGEMT-Easy and b-actin/ pGEMT, gift from Assoc. Prof. Minchin, Department Pharmacology, UWA) containing the amplified region of each gene were used to establish a standard curve which was run with every batch of samples. Product formation was monitored at the end of each extension phase. The best fit of the standards using the method of least squares was used to calculate the initial template concentration in the unknowns using the LightCyclert software. TNFa mRNA was then adjusted relative to the level of b-actin mRNA to control for variations between sample RNA concentrations.
Flow cytometric analysis of membrane CD14 and intracellular TNFa After incubation, PBMC were placed on ice for 20 min to ensure complete detachment of cells from the tube wall. PBMC were washed in PBS (without Ca 2+ and Mg 2+ ) supplemented with 1% BSA and 0.2% sodium azide. Intraprept Permeabilization Reagent (Immunotech) was used to perform simultaneous surface and intracellular antigen staining. Cell lineage markers, CD45 and CD14, were detected with anti-human ECD (clone J33, Immunotech) and anti-human FITC conjugated (clone 188, Immunotech) antibodies, respectively. The cells were then fixed, washed and permeabilised. Intracellular TNFa was detected using anti-TNFa-phycoerythrin (PE) (clone 188, Immunotech). Isotype-matched negative monoclonal antibody reagents conjugated with FITC and PE were used as negative controls. All measurements were performed on a Coulter s EPICS s XL-MCL Flow Cytometer and analysed using the Coulter XL List Mode Data Analysis program. CD45 and side scatter characteristics were used to gate for live cells and the monocyte and lymphocyte populations. Gates were set on the monocyte population using the CD14 and TNFa isotype matched controls as reference (o1% CD14 positive cells and TNFa positive cells above gate).
Statistical analysis
Statistical analysis was performed using SPSS version 7.5 software. Differences in means was assessed by MannWhitney U or T tests. A Po0.05 was considered to be significant.
